ReviewJournal of cellular physiology2019
MicroRNA replacement therapy in cancer.
Review in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives.Frontiers in pharmacology · 2025Pooled it
- The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review.BioMed research international · 2024Pooled it
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- Integrated analyses reveal a potential role for PFKFB4 in M2 macrophage polarization and hepatocellular carcinoma progression.Cancer cell international · 2026Article
- Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs.NPJ vaccines · 2026Review
- Nanoparticle-Based miRNA Therapeutics in Breast Cancer Highlighting Design Strategies and Translational Potential.International journal of nanomedicine · 2026Review
- Small RNAs, big impact: microRNAs in malaria pathogenesis, therapeutic opportunities, and challenges.Frontiers in cellular and infection microbiology · 2026Review
- miR-320d Is Associated with Reduced Nasopharyngeal Carcinoma Progression, Potentially through the NF-κB/IL-8 Axis-Mediated Inhibition of Neutrophil Extracellular Trap Formation.Oncology research · 2026Article
- MicroRNAs in cancer: biogenesis, biomarkers and therapeutic strategies.Frontiers in medicine · 2026Review
- An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update.Epigenetics · 2025Review
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Progress in the study of anti-tumor effects and mechanisms of vitexin.Pharmacological reports : PR · 2025Review
- Dual-regulatory miRNAs: master regulators and therapeutic targets in bone-metastatic breast cancer.Frontiers in molecular biosciences · 2025Review
- Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy.Oncology research · 2025Review
- Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- MicroRNA‑24 alleviates colorectal cancer progression via a rs28382740 single nucleotide polymorphism in the long noncoding region of X‑linked inhibitor of apoptosis protein.Oncology letters · 2024Article
- Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors.GeroScience · 2024Review
- Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma.Virulence · 2024Review
- MiRNAs as new potential biomarkers and therapeutic targets in brain metastasis.Non-coding RNA research · 2024Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the recent progress in cancer management approaches, the mortality rate of cancer is still growing and there are lots of challenges in the clinics in terms of novel therapeutics. MicroRNAs (miRNA) are regulatory small noncoding RNAs and are already confirmed to have a great role in regulating gene expression level by targeting multiple molecules that affect cell physiology and disease development. Recently, miRNAs have been introduced as promising therapeutic targets for cancer treatment. Regulatory potential of tumor suppressor miRNAs, which enables regulation of entire signaling networks within the cells, makes them an interesting option for developing cancer therapeutics. In this regard, over recent decades, scientists have aimed at developing powerful and safe targeting approaches to restore these suppressive miRNAs in cancerous cells. The present review summarizes the function of miRNAs in tumor development and presents recent findings on how miRNAs have served as therapeutic agents against cancer, with a special focus on tumor suppressor miRNAs (mimics). Moreover, the latest investigations on the therapeutic strategies of miRNA delivery have been presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.